文献速递免疫规划传染病防控与疫情报告

四价脑膜炎球菌结合疫苗在印度和南非健康人群中的III期随机研究

A phase III randomized study: Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine in healthy adults, adolescents, and children in India and healthy adolescents and children in South Africa.
PubMed 文献 · Vaccine · 2026-10-05

这项III期随机研究评估了单剂MenACYW-TT对比MenACYW-DT和MenPS-ACWY在印度成人、儿童青少年及南非儿童青少年中的免疫原性和安全性,共纳入1328名受试者。主要目标达成:在2-17岁人群中,MenACYW-TT对四种血清群的血清保护率(hSBA滴度≥1:8)与MenACYW-DT相比非劣效(95%CI下限>-10%)。MenACYW-TT在印度成人中免疫原性强,安全性与对照疫苗相当,未报告疫苗相关严重不良事件。

要点

  • MenACYW-TT在2-17岁人群中免疫原性非劣效于MenACYW-DT。
  • 印度18-55岁及≥56岁成人中MenACYW-TT免疫原性强。
  • 安全性与已上市对照疫苗相当,无疫苗相关严重不良事件。

核心结论

  • 单剂MenACYW-TT在2-17岁儿童青少年中诱导的免疫应答非劣效于MenACYW-DT,安全性相当。
  • MenACYW-TT在印度成人、儿童青少年及南非儿童青少年中具有良好的免疫原性和耐受性。

研究设计与样本

  • III期随机研究,共纳入1328名受试者,按年龄分为三个队列:印度18-55岁成人(N=198)、印度≥56岁成人(N=200)、印度和南非2-17岁儿童青少年(各N=465)。
  • 免疫原性采用人补体血清杀菌试验(hSBA)评估,主要目标为证明MenACYW-TT对比MenACYW-DT在2-17岁人群中第30天hSBA滴度的非劣效性。

主要发现

  • 主要目标达成:第30天时,针对所有四种血清群达到血清保护(hSBA滴度≥1:8)的受试者百分比差异的95%置信区间下限大于-10%。
  • MenACYW-TT在印度18-55岁和≥56岁成人中显示出稳健的免疫原性。
  • 接种MenACYW-TT与对照疫苗的受试者中, solicited注射部位和全身反应发生率相当。
  • 未报告疫苗相关严重不良事件、研究中止或死亡。

关键数值与推荐

  • 非劣效性界值:血清保护率差异的95%CI下限>-10%。
  • 血清保护定义为hSBA滴度≥1:8。

临床怎么用

  • 在2-17岁儿童青少年中,MenACYW-TT可作为MenACYW-DT的替代选择,免疫应答非劣效且安全性相当。
  • 在印度成人(18-55岁及≥56岁)中,单剂MenACYW-TT具有良好免疫原性和耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MenACYW-TT is a quadrivalent meningococcal conjugate vaccine approved for individuals aged ≥6 weeks. This Phase III study evaluated the immunogenicity and safety of a single dose of MenACYW-TT versus MenACYW-DT and MenPS-ACWY in healthy adults, adolescents, and children in India and in healthy adolescents and children in South Africa. METHODS: In total, 1,328 participants were randomized by age into three cohorts (Cohort Ia: adults aged 18-55 years, India [N=198]; Cohort Ib: adults aged ≥56 years, India [N=200]; Cohort II: children and adolescents aged 2-17 years, India [N=465] and South Africa [N=465]). The immunogenicity of vaccines was assessed with a serum bactericidal assay using human complement (hSBA). The primary objective was to demonstrate the non-inferiority of immunogenicity of a single dose of MenACYW-TT versus MenACYW-DT in children and adolescents aged 2-17 years in terms of hSBA titers in India and South Africa. RESULTS: The primary objective was met. The non-inferiority of MenACYW-TT versus MenACYW-DT was demonstrated on post-vaccination Day 30 in participants aged 2-17 years. The lower limit of the 95% confidence interval for the difference in the percentages of the participants achieving seroprotection (hSBA titers ≥1:8) against all four serogroups was greater than -10%. MenACYW-TT demonstrated robust immunogenicity in adults aged 18-55 years and ≥56 years in India. The rates of solicited injection site and systemic reactions were comparable between the participants who received MenACYW-TT versus licensed comparator vaccines. No vaccine-related serious adverse events, study discontinuations, or deaths were reported. CONCLUSIONS: A single dose of MenACYW-TT induced non-inferior immune responses and a comparable safety profile versus MenACYW-DT in children and adolescents aged 2-17 years. MenACYW-TT was well tolerated and immunogenic in adults, adolescents, and children in India and in adolescents and children in South Africa.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bavdekar A, Chansinghakul D, Dhati RM, et al. A phase III randomized study: Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine in healthy adults, adolescents, and children in India and healthy adolescents and children in South Africa. Vaccine. 2026. PMID: 42832931. doi:10.1016/j.vaccine.2026.129186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。